What’s in Eloxx Pharmaceuticals, Inc. (ELOX) After Reaching 52-Week High?

June 14, 2018 - By Vivian Currie

The stock of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) hit a new 52-week high and has $22.37 target or 6.00 % above today’s $21.10 share price. The 5 months bullish chart indicates low risk for the $705.31M company. The 1-year high was reported on Jun, 14 by Barchart.com. If the $22.37 price target is reached, the company will be worth $42.32M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 3.89% or $0.79 during the last trading session, reaching $21.1. About 127,270 shares traded or 29.26% up from the average. Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) has risen 234.17% since June 14, 2017 and is uptrending. It has outperformed by 221.60% the S&P500.

More notable recent Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) news were published by: Streetinsider.com which released: “Eloxx Pharmaceuticals (ELOX) Presents Positive New Data for Lead Investigational Drug, ELX-02 at ECFS” on June 08, 2018, also Seekingalpha.com with their article: “Key events next week – healthcare” published on June 01, 2018, Prnewswire.com published: “Neovasc Announces Appointment of Steve Rubin as Chairman of the Board and General Update” on June 11, 2018. More interesting news about Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) were released by: Benzinga.com and their article: “Benzinga’s Daily Biotech Pulse: AstraZeneca’s Q1, Novartis-Amgen Migraine Drug Approved” published on May 18, 2018 as well as Globenewswire.com‘s news article titled: “Eloxx Pharmaceuticals Presents Positive New Data for Lead Investigational Drug, ELX-02, at the 41st European Cystic …” with publication date: June 08, 2018.

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. The company has market cap of $705.31 million. The Company’s lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: